Free Biopharma Daily Stock Updates - 06/21/21

$XBI $135 +1%

---

Want to access our searchable Catalyst Calendar of over 1,000 biotech stock events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!

---

Covid Updates

$GILD +1% Gilead’s Veklury® (Remdesivir) Associated With a Reduction in Mortality Rate in Hospitalized Patients With COVID-19 Across Three Analyses of Large Retrospective Real-World Data Sets. source

$VIR +6% GSK and Vir Biotechnology Announce Continuing Progress of the COMET Clinical Development Program for Sotrovimab. source

$RDHL -1% RedHill Biopharma Announces Presentation of Positive Oral Opaganib Phase 2 Data in COVID-19. source

$TNXP -7% Tonix Pharmaceuticals Announces Program to Develop TNX-102 SL for the Treatment of Long COVID Syndrome, also Known as Post-Acute Sequelae of COVID-19 (PASC). source

$TBPH +0% Theravance Biopharma, Inc. Announces Top-Line Results From Phase 2 Study of Nezulcitinib In Patients Hospitalized With Acute Lung Injury Due to COVID-19. source

Pipeline Updates

$ICPT +5% INTERCEPT TO PRESENT NEW NASH AND PBC DATA AT THE DIGITAL INTERNATIONAL LIVER CONGRESS™ 2021. source

$SAVA +13% Cassava Sciences Selects Clinical Research Organization for Phase 3 Clinical Program in Alzheimer’s Disease. source

$CAPR +2% Capricor Therapeutics to Present Findings from HOPE-2 Open-Label Extension Study at Parent Project Muscular Dystrophy (PPMD) 2021 Virtual Annual Conference. source

$MBRX -2% Moleculin Announces First Subject Enrolled and Dosed in Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Sarcoma Lung Metastases. source

$CYDY -3% CytoDyn Inc. Announces Positive Preliminary Results of Unblinded Data from Long-Haulers Trial Showing Greater Improvement in Leronlimab Group over Placebo in 18 of 24 Symptoms. source

$SPRB -12% Spruce Biosciences Announces Publication of Phase 2 Results for Tildacerfont in Journal of Clinical Endocrinology and Metabolism. source

$CTMX -2% CytomX Therapeutics Announces Publication of First-in-Human Data for CX-2029 in Clinical Cancer Research. source

$OPK +2% OPKO Health to Develop and Commercialize RAYALDEE® in Greater China with Nicoya Therapeutics. source

$CBAY +2% CymaBay Therapeutics Presents Positive PBC Data at the International Liver Congress™ 2021. source

$AVXL +2% Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Biomarker Correlated with Efficacy Endpoints in Placebo-Controlled U.S. Phase 2 Clinical Trial for the Treatment of Adult Patients with Rett Syndrome source

$AGIO +14% Agios Submits New Drug Application to FDA for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency. source

$OYST -3% Oyster Point Pharma Announces Enrollment of First Subject in the OLYMPIA Phase 2 Clinical Trial of OC-01 (varenicline) Nasal Spray for Patients with Neurotrophic Keratopathy. source

$TSHA +1% Taysha Gene Therapies Announces Publication of Natural History Data for TSHA-120 in Giant Axonal Neuropathy in the Journal, Brain. source

$APLT +6% Applied Therapeutics to Present on Diabetic Cardiomyopathy and Prevalence of Disease at the 81st Scientific Sessions of the 2021 Annual Meeting of the American Diabetes Association. source

$MNOV +12% MediciNova Announces Positive Results from Phase 2 Trial of MN-166 (ibudilast) in Alcohol Use Disorder Published in Nature’s Translational Psychiatry Journal. source

$ALBO +3% Albireo Announces Expanded Phase 3 Data on Bylvay™ (odevixibat) and A3907 at Upcoming EASL International Liver Congress. source

$TARS -17% Tarsus Pharmaceuticals, Inc. Announces Positive Results of Saturn-1 Pivotal Trial Evaluating TP-03 for the Treatment of Demodex Blepharitis. source

---

Posted by FS/DV